Tumour hypoxia sensor: A state of the art in oral cancer liquid biopsy

References

[1] Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008;8:180-192.

[2] Ye Y, Hu Q, Chen H, et al. Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nat Metab. 2019;1:431-444.

[3] Muz B, de la Puente P, Azab F, et al. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015;3:83-92.

[4] Vaupel P, Höckel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal. 2007;9:1221-1235.

[5] Sebestyén A, Kopper L, Dankó T, et al. Hypoxia signaling in cancer: from basics to clinical practice. Pathol Oncol Res. 2021;27:1609802.

[6] Vaupel P, Flood AB, Swartz HM. Oxygenation status of malignant tumors vs. normal tissues: critical evaluation and updated data source based on direct measurements with pO2 microsensors. Appl Magn Reson. 2021;52:1451-1479.

[7] Zhuang Y, Liu K, He Q, et al. Hypoxia signaling in cancer: implications for therapeutic interventions. MedComm (2020). 2023;4:e203.

[8] Chia K, Fleming IN, Blower PJ. Hypoxia imaging with PET: which tracers and why? Nucl Med Commun. 2012;33:217-222.

[9] Fleming IN, Manavaki R, Blower PJ, et al. Imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2015;112:238-250.

[10] Mason RP, Zhao D, Pacheco-Torres J, et al. Multimodality imaging of hypoxia in preclinical settings. Q J Nucl Med Mol Imaging. 2010;54:259-280.

[11] Kumar S, Dhar R, Kumar LBSS, et al. Theranostic signature of tumor-derived exosomes in cancer. Med Oncol. 2023;40:321.

[12] Dhar R, Mallik S, Devi A. Exosomal microRNAs (exoMIRs): micromolecules with macro impact in oral cancer. 3 Biotech. 2022;12:155.

[13] Dhar R, Devi A. Exosomes Barcoding: a smart approach for cancer liquid biopsy. J Liquid Biopsy. 2023;2:100129.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.